CN109998101A - 一种适用心脏调养人群的宇航民用营养配方 - Google Patents
一种适用心脏调养人群的宇航民用营养配方 Download PDFInfo
- Publication number
- CN109998101A CN109998101A CN201910077599.1A CN201910077599A CN109998101A CN 109998101 A CN109998101 A CN 109998101A CN 201910077599 A CN201910077599 A CN 201910077599A CN 109998101 A CN109998101 A CN 109998101A
- Authority
- CN
- China
- Prior art keywords
- haematococcus pluvialis
- parts
- astaxanthin
- heart
- grape pip
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 238000009472 formulation Methods 0.000 title claims abstract description 23
- 235000015097 nutrients Nutrition 0.000 title claims abstract description 22
- 241000168517 Haematococcus lacustris Species 0.000 claims abstract description 81
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims abstract description 52
- 235000013793 astaxanthin Nutrition 0.000 claims abstract description 52
- 239000001168 astaxanthin Substances 0.000 claims abstract description 52
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims abstract description 52
- 229940022405 astaxanthin Drugs 0.000 claims abstract description 52
- 241000219095 Vitis Species 0.000 claims abstract description 41
- 235000009754 Vitis X bourquina Nutrition 0.000 claims abstract description 41
- 235000012333 Vitis X labruscana Nutrition 0.000 claims abstract description 41
- 235000014787 Vitis vinifera Nutrition 0.000 claims abstract description 41
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims abstract description 38
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims abstract description 22
- 239000000843 powder Substances 0.000 claims abstract description 21
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 19
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 18
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims abstract description 16
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 16
- 230000005684 electric field Effects 0.000 claims abstract description 16
- 238000012545 processing Methods 0.000 claims abstract description 15
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 12
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 12
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 12
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000000811 xylitol Substances 0.000 claims abstract description 12
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 12
- 229960002675 xylitol Drugs 0.000 claims abstract description 12
- 235000010447 xylitol Nutrition 0.000 claims abstract description 12
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims abstract description 11
- 235000019341 magnesium sulphate Nutrition 0.000 claims abstract description 11
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 10
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 10
- 229940046009 vitamin E Drugs 0.000 claims abstract description 10
- 239000011709 vitamin E Substances 0.000 claims abstract description 10
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 9
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 9
- 239000011718 vitamin C Substances 0.000 claims abstract description 9
- 239000001963 growth medium Substances 0.000 claims description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000008169 grapeseed oil Substances 0.000 claims description 11
- 241000209094 Oryza Species 0.000 claims description 10
- 235000007164 Oryza sativa Nutrition 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 10
- 235000009566 rice Nutrition 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 238000000265 homogenisation Methods 0.000 claims description 8
- 230000002255 enzymatic effect Effects 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 239000000314 lubricant Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 238000007710 freezing Methods 0.000 claims description 5
- 230000008014 freezing Effects 0.000 claims description 5
- 238000004880 explosion Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000002609 medium Substances 0.000 claims description 4
- 230000001007 puffing effect Effects 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 230000003698 anagen phase Effects 0.000 claims description 3
- 238000013329 compounding Methods 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- 238000005286 illumination Methods 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 3
- 235000019198 oils Nutrition 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 210000001367 artery Anatomy 0.000 claims description 2
- 239000007640 basal medium Substances 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
- 230000036541 health Effects 0.000 abstract description 8
- 235000013305 food Nutrition 0.000 abstract description 6
- 150000003254 radicals Chemical class 0.000 abstract description 6
- 229930014669 anthocyanidin Natural products 0.000 abstract description 5
- 150000001452 anthocyanidin derivatives Chemical class 0.000 abstract description 5
- 235000008758 anthocyanidins Nutrition 0.000 abstract description 5
- 230000003078 antioxidant effect Effects 0.000 abstract description 5
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 3
- 230000005855 radiation Effects 0.000 abstract description 3
- 239000000047 product Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- 239000000306 component Substances 0.000 description 12
- 208000024172 Cardiovascular disease Diseases 0.000 description 11
- 241000168525 Haematococcus Species 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 230000003647 oxidation Effects 0.000 description 9
- 238000007254 oxidation reaction Methods 0.000 description 9
- 238000011160 research Methods 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 241000195493 Cryptophyta Species 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 208000019622 heart disease Diseases 0.000 description 4
- 230000004217 heart function Effects 0.000 description 4
- 206010019280 Heart failures Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229940087559 grape seed Drugs 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108010059892 Cellulase Proteins 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 2
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 2
- 235000009685 Crataegus X maligna Nutrition 0.000 description 2
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 2
- 235000009486 Crataegus bullatus Nutrition 0.000 description 2
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 2
- 235000009682 Crataegus limnophila Nutrition 0.000 description 2
- 240000000171 Crataegus monogyna Species 0.000 description 2
- 235000004423 Crataegus monogyna Nutrition 0.000 description 2
- 235000002313 Crataegus paludosa Nutrition 0.000 description 2
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 2
- 235000003143 Panax notoginseng Nutrition 0.000 description 2
- 241000180649 Panax notoginseng Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 244000046146 Pueraria lobata Species 0.000 description 2
- 235000010575 Pueraria lobata Nutrition 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 240000003768 Solanum lycopersicum Species 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 240000000851 Vaccinium corymbosum Species 0.000 description 2
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 2
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N aldehydo-N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000021014 blueberries Nutrition 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 229940106157 cellulase Drugs 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 229950006238 nadide Drugs 0.000 description 2
- 235000013557 nattō Nutrition 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000004108 pentose phosphate pathway Effects 0.000 description 2
- 229940026314 red yeast rice Drugs 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000195627 Chlamydomonadales Species 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 150000000847 D-riboses Chemical class 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 240000001131 Nostoc commune Species 0.000 description 1
- 235000013817 Nostoc commune Nutrition 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003130 cardiopathic effect Effects 0.000 description 1
- 230000036996 cardiovascular health Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 230000005672 electromagnetic field Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229960003390 magnesium sulfate Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229940086319 nattokinase Drugs 0.000 description 1
- 108010073682 nattokinase Proteins 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- -1 superoxide ion Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明属于食品保健品加工技术领域,具体涉及一种适用心脏调养人群的宇航民用营养配方,包括D‑核糖3‑6份;葡萄籽粉20‑40份;雨生红球藻100份;硫酸镁0.02‑0.5份;维生素E0.2‑0.6份;维生素C0.1‑1.0份;麦芽糊精5‑20份;木糖醇5‑10份。配方中的雨生红球藻为进行虾青素富集后的雨生红球藻,所述雨生红球藻中虾青素的富集采用强脉冲电场结合脉冲微波培养富集。该产品配方中雨生红球藻中虾青素含量高,活性强,同时与葡萄籽粉中的花青素与D‑核糖相互促进,增加了产品的抗氧化活性,可有清除解宇航员在太空环境中由于强电离、强辐射等引起的自由基,保证宇航员心脑血管健康。
Description
技术领域
本发明属于食品保健品加工技术领域,具体涉及一种适用心脏调养人群的宇航民用营养配方。
背景技术
由于太空环境的强辐射、强电离、工作强度大等特性,给太空作业的宇航员的身体会造成较大的伤害,一旦宇航员的心脏功能出现异常将直接影响宇航员的太空工作,甚至直接导致宇航员退役。
心脏是人体的重要器官,是循环系统的动力泵,将全身的血液、营养、氧气等输送到组织的各个细胞,并将代谢废弃物带走。心脏一旦出现问题将对身体和生命造成极大的威胁。从1990年起,中国心血管疾病持续成为居民首位死亡原因。2017年中国心血管病报告显示,我国心血管病患病率及死亡率仍处于上升阶段,心血管病现患人数2.9亿,其中脑卒中1300万,冠心病1100万,肺源性心脏病500万,心力衰竭450万,风湿性心脏病250万,先天性心脏病200万,高血压2.7亿。
早在2013年国人的心血管健康状况就已经被警示,很多研究也说明了其形势严峻。世界医学权威杂志《柳叶刀》发布了《全球疾病负担报告2013》,该研究评估了1990年~2013年间188个国家的死亡情况,由华盛顿大学健康指标和评估研究所(IHME)领导的国际研究人员联盟指导进行。报告显示,在中国,最致命的三种疾病是脑卒中、冠心病以及慢性阻塞性肺病,这三种疾病造成的死亡人数占2013年全部死亡人数的46%。而以世界卫生组织的定义,心血管病是心脏和血管疾患引起的,包括冠心病、脑卒中、高血压、心衰等。换言之,中国最致命三大健康杀手,心血管疾病占去两个。据国家心血管病中心发布的《中国心血管病报告2012》数据显示,中国心血管病现患人数已高达2.9亿,即每10个成年人中就有2人患心血管病,每年约350万人死于心血管病,相当于每10秒就有1人死于心血管病。而另一个由国家心血管病中心联合阜外心血管病医院组织实施的临床研究显示,在中国,心血管病患者的住院人数在2001年至2010年的十年间增加了四倍多。2001年因心脏病住院的平均每十万人中有3.7人,到2010年就飙升至15.8人。
目前心脏病的治疗并没有特效药物,只能通过长期服用药物来缓解和改善症状,但是长期服药会增加人体肾脏、肝脏等的压力,影响其他脏器的功能和健康。因此研究开发一种具有养护心脏功能的保健食品不仅对宇航员的心脏具有养护功能,同时对改善我国居民的心血管健康具有重要意义。
中国专利CN 105614890 A公开了一种心脏养护食品及其制备方法。该食品包括如下重量份的组分:蓝莓30-45份、虾壳28-45份、蟹壳28-45份、纳豆15-25份、红曲米25-38份、西红柿25-40份、三七12-20份;制备方法是提取出蓝莓中的花青素、虾壳与蟹壳中的虾青素和壳聚糖、红曲米中的洛伐他汀、纳豆中的纳豆激酶、西红柿中的番茄红素以及三七中的三七皂甙,分别在35℃~42℃条件下真空干燥后混合在一起。该产品能缓解甚至治疗心脏疾病,且安全健康、无副作用。
中国专利CN 103652848 A公开了一种具有心脏养护功能的功能食品制备方法。以辅酶Q10、山楂、葛根为原料,重量百分比分别为:山楂:5~80%;辅酶Q10 5~20%;葛根10~35%。该产品的制备方法包括原料成分的比例含量及功效成分的提取,制剂的制备方法。该食疗制剂具有营养心脏、促进脏腑平衡、恢复心脏功能的功效作用。
发明内容
上述发明专利虽然均具有养护心脏的功能,但是针对宇航员这类长期暴露在高辐射、高电离环境中的脑力及体力劳动强度均较大的特殊群体并没有凸显出明显的效果和作用。本发明旨在提供一种适用心脏调养人群的宇航民用营养配方,为实现上述目的,本发明通过以下技术方案实现:
一种适用心脏调养人群的宇航民用营养配方,由以下重量份的物质制备而成:D-核糖3-6份;葡萄籽粉20-40份;雨生红球藻100份;硫酸镁0.02-0.5份;维生素E 0.2-0.6份;维生素C 0.1-1.0份;麦芽糊精5-20份;木糖醇5-10份。
做为具体技术方案,所述雨生红球藻为进行虾青素富集后的雨生红球藻,雨生红球藻中虾青素的富集采用强脉冲电场结合微波培养富集。
做为具体技术方案,所述雨生红球藻中虾青素的富集方法为:(3-1)雨生红球藻的培养:选用Bold’s Basal Medium(BBM)为基础培养基,将纯化过的雨生红球藻转接到培养基中,25℃,光强65μE/(m2s)的红光照射,持续通入0.1vvm的无菌空气,培养至对数生长期;(3-2)富集培养基处理:将缺氮BBM培养基置于强脉冲电场中,脉冲宽度2-5us,流速60ml/min,脉冲频率400Hz,脉冲强度25-45kv/cm,脉冲处理时间100-300us;(3-3)虾青素的富集培养:将步骤(3-1)培养完成的雨生红球藻接种至步骤(3-2)中的培养基中,光照强度2500LX,培养温度20-35℃,培养2-3天,之后将雨生红球藻置于微波条件下培养,微波剂量为1-10kw/kg,微波处理时间2-5min,控制培养基温度在25-35℃,之后继续放入培养箱中培养3-7天,离心分离获得富集虾青素雨生红球藻。
做为具体技术方案,所述营养配方采用以下方法制备而成:(4-1)葡萄籽粉制备:将葡萄籽清洗干净,膨化干燥至含水量小于10%,水酶法提取葡萄籽中的油脂成分,制得葡萄籽油和葡萄籽粕,将提取葡萄籽油之后的葡萄籽粕烘干至含水量小于10%,超微粉碎后过500-800目筛,取筛下物,备用;(4-2)雨生红球藻的制备:取富集虾青素后的雨生红球藻细胞,分散于0℃的VC溶液中,放置于-4℃1-2h,移入-5℃—-25℃的环境中冷冻10-24h,之后于5—-4℃条件下机械磨浆后超高压均质,均质压力100mpa-180mpa,往复磨浆-均质步骤处理2-3次后加入麦芽糊精搅拌均匀后冷冻干燥至含水量小于5%制得雨生红球藻;(4-3)复配:将配方质量的VE用步骤(4-1)中的葡萄籽油溶解后加入提取葡萄籽油后的葡萄籽粕中,搅拌混合均匀后加入步骤(4-2)制备的雨生红球藻,混合均匀,之后加入配方质量的D-核糖,硫酸镁,木糖醇,混合均匀后包装制得本发明营养配方。
做为优选技术方案,所述雨生红球藻分散至VC溶液中时细胞固含量与液体的质量比为1:1~1:2;VC溶液浓度为1-3mg/ml。
膨化干燥过程中采用干燥方法为微波膨化干燥或变压差膨化干燥。水酶法提取葡萄籽中的油脂成分所用的酶为纤维素酶、蛋白酶、淀粉酶组成的复合酶系。酶解过程中采用超声波辅助提取。
本发明采用D-核糖、葡萄籽粉、雨生红球藻、硫酸镁、维生素E、维生素C、麦芽糊精、木糖醇为主要成分,产品中富含丰富的抗氧化物质,可有效改善由于外部环境导致的心脏及血液中的过氧化离子,降低机体的氧化,有效改善心脑血管健康。
D-核糖是一种功能性的戊糖,又叫D-呋喃核糖,是生物体内核糖核酸、某些维生素和核苷酸类辅酶(如NAD、NADH、FAD、ADP、UDP、CDP、GDP等)的组成成分,具有十分重要的生理作用。有研究表明D-核糖对先天性心脏衰竭导致呼吸困难有辅助治疗作用,D-核糖可以提供一种独特的代写方法来改善心脏功能。外源性的D-核糖对大鼠心肌缺血再灌注损伤的保护作用也有研究,外源性核糖在磷酸戊糖途径较为活跃的组织器官如肝脏、肾脏、红细胞等中,可作为磷酸戊糖途径的底物,加速磷酸戊糖循环,产生还原当量,以还原型辅酶II的方式提高机体氧化系统的防御能力,提高氧化酶的活性,加速自由基的清除速度,核糖可以明显提高各组织器官内还原型谷胱甘肽的含量,加速过氧化氢的清除速度,对清除缺氧产生的过量自由基、抑制细胞膜脂质过氧化、保护细胞膜的完整性具有重要意义。
葡萄籽粉:葡萄籽中含有丰富的葡萄多酚,具有很强的抗氧化作用。可明显提高血管抵抗力,降低(毛细血管)的渗透性。随着年龄的增长,动脉中弹性纤维逐渐氧化而变硬。这种硬化是导致老年人高血压的主要原因。原花青素提高血管弹性而降低血压。患者服用原花青素胶囊一段时间后,血压会明显下降。动物实验及临床研究还表明,原花青素可降低(胆固醇)水平,缩小沉积于血管壁上的胆固醇沉积物体积。原花青素软胶囊还可以通过抑制血管紧张逆转醇的活性来降低血压。
雨生红球藻:雨生红球藻(Haematococcus pluvialis)是一种单细胞真核绿藻,隶属绿藻门,团藻目、红球藻科、红球藻属。由于该藻能大量累积虾青素(Astaxanthin)而呈现红色,故取名红球藻。在特定的环境下能大量累积虾青素,含量可达细胞干重的1.5-4%,因此,雨生红球藻是公认最好的用于天然虾青素开发的生物资源,已成为国际天然虾青素产业的研究热点。雨生红球藻软胶囊作为营养保健食品通过了美国FDA批准,可有效预防血液中LDL-胆固醇的氧化损伤、保护皮肤抵御紫外辐射损伤以及缓解年龄相关性黄斑变性等。我国已于2010年经卫生部批准雨生红球藻作为新资源食品。雨生红球藻细胞中的天然虾青素是一种具有高抗氧化活性的类胡萝卜素,它具有10倍于β-胡萝卜素抗氧化效果和550倍于维生素E的抑制脂质过氧化反应特性,它不能在动物体内合成,但它是人体和动物生命活动所必须的物质。研究表明,虾青素可增强生物体的免疫力,可辅助心血管疾病、免疫系统、炎症和神经退行性等疾病康复,同时具有抗衰老和修复紫外线损伤的功能。
本发明具有以下有益效果:
1.有效成分活性高,浓度高
本发明采用D-核糖、葡萄籽粉、雨生红球藻为主要配方,保证产品功效具有较强的抗氧化性和清除自由基的作用在制备加工过程中采用虾青素高强电磁场富集技术、高效破壁技术、纯化复配技术等保证产品中高浓度、高纯度的虾青素、花青素等物质的生物活性,使得产品活性高,有效成分浓度高。
2.标本兼治、内外兼修,提高机体抗氧化能力
本发明核心成分D-核糖、花青素、虾青素三种有效成分相互配合,相互促进,自由基清除率大大提高。花青素、虾青素做为强还原性物质能够有效的清除体内由于氧化而造成的自由基,而D-核糖通过加速磷酸戊糖循环,增加体内的还原当量,提高抗氧化酶活性等抑制细胞内的氧化过程。三种物质相辅相成,从氧化过程和氧化物质两方面入手,可大大降低细胞氧化及由于氧化而产生的自由基,标本兼治,内外兼修,有机结合,大大提高机体脏器抗氧化能力,对于长期处于电离辐射环境中的宇航员同样具有较好的效果。制备过程中将雨生红球藻中的虾青素进行大量富集,其含量可达到细胞干重的5%-6%,大大超过普通方法培养的雨生红球藻中的虾青素含量。
3.不引入外来物料,产品安全性高
在葡萄籽粉的制备过程通过水酶法提取葡萄籽中的油脂成分,将油脂成分与产品中的油溶性配方混合后再进行所有物料的混合,保证物料混合均匀的同时不引入外来物质,不改变产品天然属性,产品安全性更高。雨生红球藻破壁后加入麦芽糊精,既完成了产品配方的调配又保护了破壁后雨生红球藻中的有效成分,保证了产品的生物活性,采用低温冷冻干燥过程完成产品脱水,避免高温造成的产品氧化变质。
具体实施方式
下面结合具体实施方式对本发明做进一步说明,需要指出的是以下实施方式仅是以例举的形式对本发明所做的解释性说明,但本发明的保护范围并不仅限于此,所有本领域的技术人员以本发明的精神对本发明所做的等效的替换均落入本发明的保护范围。
实施例1
一种适用心脏调养人群的宇航民用营养配方,由以下重量份的物质制备而成:D-核糖3-6份;葡萄籽粉20-40份;雨生红球藻100份;硫酸镁0.02-0.5份;维生素E0.2-0.6份;维生素C0.1-1.0份;麦芽糊精5-20份;木糖醇5-10份。
实施例2
一种适用心脏调养人群的宇航民用营养配方,包括D-核糖6g;葡萄籽粉40g;雨生红球藻100g;硫酸镁0.02g份;维生素E0.3g;维生素C0.8g份;麦芽糊精15g;木糖醇10g。雨生红球藻为进行虾青素富集后的雨生红球藻,雨生红球藻中虾青素的富集采用强脉冲电场结合微波培养富集。具体是在雨生红球藻的固定期培养过程中移入缺氮培养基上进行培养,配制好的缺氮培养基放入强脉冲电场中处理,通过强脉冲电场对培养基进行充电-放电处理,使得培养基中的过氧化物含量升高,培养基中的超氧自由基含量升高后再接入雨生红球藻进行培养,培养过程中采用微波处理处理一次。强脉冲电场结合微波培养富集后雨生红球藻中的虾青素含量大大升高。检测了不同培养方法雨生红球藻中虾青素的含量如下表1所示。
表1不同处理条件下雨生红球藻中虾青素浓度
处理方法 | 虾青素浓度(ug/ml) |
普通培养方法 | 1.3-1.5 |
脉冲电场处理培养基 | 1.7-2.1 |
微波培养 | 1.5-1.8 |
脉冲电场联合微波处理 | 2.1-2.7 |
实施例3
一种适用心脏调养人群的宇航民用营养配方,包括D-核糖6g;葡萄籽粉40g;雨生红球藻100g;硫酸镁0.02g份;维生素E0.3g;维生素C0.8g份;麦芽糊精15g;木糖醇10g。雨生红球藻为进行虾青素富集后的雨生红球藻,雨生红球藻中虾青素的富集采用强脉冲电场结合微波培养富集。
雨生红球藻中虾青素的富集方法为:(3-1)雨生红球藻的培养:选用Bold’sBasalMedium(BBM)为基础培养基,将纯化过的雨生红球藻转接到培养基中,25℃,光强65μE/(m2s)的红光照射,持续通入0.1vvm的无菌空气,培养至对数生长期;(3-2)富集培养基处理:将缺氮BBM培养基置于强脉冲电场中,脉冲宽度2-5us,流速60ml/min,脉冲频率400Hz,脉冲强度25-45kv/cm,脉冲处理时间100-300us;(3-3)虾青素的富集培养:将步骤(3-1)培养完成的雨生红球藻接种至步骤(3-2)中的培养基中,光照强度2500LX,培养温度20-35℃,培养2-3天,之后将雨生红球藻置于微波条件下培养,微波剂量为1-10kw/kg,微波处理时间2-5min,控制培养基温度在25-35℃,之后继续放入培养箱中培养3-7天,离心分离获得富集虾青素雨生红球藻。
以未处理的缺氮培养基为对照组,测定不同脉冲强度处理缺氮BBM培养基后,培养雨生红球藻培养5天后检测雨生红球藻中的虾青素浓度如下表2所示。
表2不同脉冲强度处理缺氮BBM培养基后雨生红球藻中虾青素含量
脉冲强度 | 虾青素浓度(ug/ml) |
0kv/cm(对照组) | 1.42 |
25kv/cm | 1.71 |
30kv/cm | 1.82 |
35kv/cm | 2.09 |
40kv/cm | 1.93 |
45kv/cm | 1.87 |
由表2可以看出,与对照组相比,不同强脉冲电场处理后雨生红球藻中的虾青素含量明显升高,但并不是强脉冲电场强度越高虾青素含量越高。
以未进行强脉冲电场处理的缺氮BBM培养基培养雨生红球藻,培养过程中采用微波处理,以未微波处理为对照组,检测不同微波剂量处理培养7天后雨生红球藻中的虾青素含量,结果如表3所示。
表3不同微波剂量处理培养后雨生红球藻中虾青素含量
微波剂量 | 虾青素浓度(ug/ml) |
0kw/kg(对照组) | 1.47 |
1kw/kg | 1.50 |
2kw/kg | 1.51 |
4kw/kg | 1.87 |
6kw/kg | 1.76 |
8kw/kg | 1.82 |
10kw/kg | 1.68 |
由表3所示,不同微波剂量处理可以明显提高雨生红球藻中虾青素含量。
实施例4
一种适用心脏调养人群的宇航民用营养配方,包括D-核糖3g;葡萄籽粉35g;雨生红球藻100g;硫酸镁0.1g;维生素E0.4g;维生素C0.7g;麦芽糊精15g;木糖醇8g。
本发明营养配方采用以下方法制备而成:(4-1)葡萄籽粉制备:将葡萄籽清洗干净,膨化干燥至含水量小于10%,水酶法提取葡萄籽中的油脂成分,制得葡萄籽油和葡萄籽粕,将葡萄籽粕烘干至含水量小于10%,超微粉碎后过500-800目筛,取筛下物即得葡萄籽粉,备用,同时测定葡萄籽的含油率;(4-2)雨生红球藻的制备:取实施例3中富集虾青素后的雨生红球藻细胞,分散于0℃的VC溶液中,放置于-4℃环境1-2h,之后移入-5℃—-25℃的环境中冷冻10-24h,取出在5—-4℃条件下机械磨浆后超高压均质,均质压力100mpa-180mpa,重复磨浆-均质步骤2-3次,测定雨生红球藻的含水量,按雨生红球藻干基重量15%加入麦芽糊精搅拌均匀后冷冻干燥至含水量小于5%制得雨生红球藻;(4-3)复配:根据葡萄籽的含油率测定配方葡萄籽粉中的葡萄籽油含量,用水酶法提取出的葡萄籽油将配方质量的VE溶解后加入配方步骤(4-1)粉碎后的葡萄籽粕中,制得配方质量的葡萄籽粉,搅拌混合均匀后加入步骤(4-2)制备的雨生红球藻,混合均匀,之后加入配方质量的D-核糖,硫酸镁,木糖醇,混合均匀后包装制得本发明营养配方。
水酶法提取葡萄籽油之前将葡萄籽采用微波膨化干燥至含水量小于10%,之后将葡萄籽粉碎至40-100目筛,取筛下物加入筛下物质量10%~20%干燥葡萄籽(未粉碎)混合。按料液质量1:1.5-2加入纯净水,25-35℃超声处理30-50min,加入纤维素酶、蛋白酶、淀粉酶组成的复合酶系,25-35℃的温度条件下超声辅助提取2-3h,-4~4℃冷冻20min,继续加热至25-35℃,提取1-2h,-4~4℃冷冻20min,离心取上清液分离葡萄籽油,下层葡萄籽粕干燥至含水量小于5%。
实施例5
一种适用心脏调养人群的宇航民用营养配方,包括D-核糖3g;葡萄籽粉35g;雨生红球藻100g;硫酸镁0.1g;维生素E0.4g;维生素C0.7g;麦芽糊精15g;木糖醇8g。上述雨生红球藻中富集虾青素后采用以下方法进行破壁处理:
5-1:取富集虾青素后的雨生红球藻细胞,分散于0℃的VC溶液中,细胞固含量与液体的质量比为1:1~1:2;VC溶液浓度为1-3mg/ml;
5-2:将上述溶液放置于-4℃环境1-2h,等待雨生红球藻慢慢形成冰晶,
5-3:将初步形成冰晶的雨生红球藻溶液转移至移入-5℃—-25℃的环境中冷冻10-24h;
5-4:完全冷冻后的雨生红球藻取出后在5—-4℃环境条件下机械研磨,冰晶被完全磨碎,同时回温解冻形成低温浆液;
5-5:将机械研磨后的低温浆液超高压均质,均质压力100mpa-180mpa;
5-6重复步骤5-4、步骤5-5 2-3次,即实现了雨生红球藻的破壁。
采用该破壁方法破壁效果好,雨生红球藻中的虾青素破坏较少,产品活性高。
Claims (5)
1.一种适用心脏调养人群的宇航民用营养配方,其特征在于,由以下重量份的物质制备而成:D-核糖3-6份;葡萄籽粉20-40份;雨生红球藻100份;硫酸镁0.02-0.5份;维生素E0.2-0.6份;维生素C 0.1-1.0份;麦芽糊精5-20份;木糖醇5-10份。
2.如权利要求1所述的一种适用心脏调养人群的宇航民用营养配方,其特征在于,所述雨生红球藻为进行虾青素富集后的雨生红球藻,所述雨生红球藻中虾青素的富集采用强脉冲电场结合脉冲微波培养富集。
3.如权利要求2所述的一种适用心脏调养人群的宇航民用营养配方,其特征在于,所述雨生红球藻中虾青素的富集方法为:(3-1)雨生红球藻的培养:选用Bold’s Basal Medium(BBM)为基础培养基,将纯化过的雨生红球藻转接到培养基中,25℃,光强65μE/(m2s)的红光照射,持续通入0.1vvm的无菌空气,培养至对数生长期;(3-2)富集培养基处理:将缺氮BBM培养基置于强脉冲电场中,脉冲宽度2-5us,流速60ml/min,脉冲频率400Hz,脉冲强度25-45kv/cm,脉冲处理时间100-300us;(3-3)虾青素的富集培养:将步骤(3-1)培养完成的雨生红球藻接种至步骤(3-2)中的培养基中,光照强度2500LX,培养温度20-35℃,培养2-3天,之后将雨生红球藻置于微波条件下培养,微波剂量为1-10kw/kg,微波处理时间2-5min,控制培养基温度在25-35℃,之后继续放入培养箱中培养3-7天,离心分离获得富集虾青素雨生红球藻。
4.如权利要求3所述的一种适用心脏调养人群的宇航民用营养配方,其特征在于,所述营养配方采用以下方法制备而成:(4-1)葡萄籽粉制备:将葡萄籽清洗干净,膨化干燥至含水量小于10%,水酶法提取葡萄籽中的油脂成分,制得葡萄籽油和葡萄籽粕,将提取葡萄籽油之后的葡萄籽粕烘干至含水量小于10%,超微粉碎后过500-800目筛,取筛下物,备用;(4-2)雨生红球藻的制备:取富集虾青素后的雨生红球藻细胞,分散于0℃的VC溶液中,-4℃条件下放置1-2h,之后移入-25℃~-5℃的环境中冷冻10~24h,之后于-4~5℃条件下机械磨浆后超高压均质,均质压力100mpa-180mpa,往复处理研磨-均质步骤2-3次后加入麦芽糊精搅拌均匀,冷冻干燥至含水量小于5%制得雨生红球藻;(4-3)复配:将配方质量的VE用步骤(4-1)中的葡萄籽油溶解后加入粉碎后的葡萄籽粕中,搅拌混合均匀后加入步骤(4-2)制备的雨生红球藻,混合均匀,之后加入配方质量的D-核糖,硫酸镁,木糖醇,混合均匀后包装制得适用心脏调养人群的宇航民用营养配方。
5.如权利要求4所述的一种适用心脏调养人群的宇航民用营养配方,其特征在于,所述雨生红球藻分散至VC溶液中时细胞固含量与液体的质量比为1:1~1:2;VC溶液浓度为1-3mg/ml。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910077599.1A CN109998101A (zh) | 2019-01-28 | 2019-01-28 | 一种适用心脏调养人群的宇航民用营养配方 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910077599.1A CN109998101A (zh) | 2019-01-28 | 2019-01-28 | 一种适用心脏调养人群的宇航民用营养配方 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109998101A true CN109998101A (zh) | 2019-07-12 |
Family
ID=67165530
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910077599.1A Pending CN109998101A (zh) | 2019-01-28 | 2019-01-28 | 一种适用心脏调养人群的宇航民用营养配方 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109998101A (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1454090A (zh) * | 2000-07-28 | 2003-11-05 | 生物能量公司 | 用于提高心血管功能的组合物和方法 |
CN101016514A (zh) * | 2007-01-26 | 2007-08-15 | 福建师范大学 | 一种采用微波法提高微藻生物量的方法 |
CN103431401A (zh) * | 2013-09-16 | 2013-12-11 | 厦门中药厂有限公司 | 一种抗氧化保健食品及其应用 |
CN105483016A (zh) * | 2016-01-25 | 2016-04-13 | 清华大学深圳研究生院 | 培养雨生红球藻的方法及应用 |
CN107460225A (zh) * | 2017-10-11 | 2017-12-12 | 广西南宁秀珀生物科技有限公司 | 连续培养雨声红球藻累积虾青素的方法 |
CN108753620A (zh) * | 2018-05-30 | 2018-11-06 | 昆明理工大学 | 一种提高雨生红球藻生物量和虾青素含量的方法 |
-
2019
- 2019-01-28 CN CN201910077599.1A patent/CN109998101A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1454090A (zh) * | 2000-07-28 | 2003-11-05 | 生物能量公司 | 用于提高心血管功能的组合物和方法 |
CN101016514A (zh) * | 2007-01-26 | 2007-08-15 | 福建师范大学 | 一种采用微波法提高微藻生物量的方法 |
CN103431401A (zh) * | 2013-09-16 | 2013-12-11 | 厦门中药厂有限公司 | 一种抗氧化保健食品及其应用 |
CN105483016A (zh) * | 2016-01-25 | 2016-04-13 | 清华大学深圳研究生院 | 培养雨生红球藻的方法及应用 |
CN107460225A (zh) * | 2017-10-11 | 2017-12-12 | 广西南宁秀珀生物科技有限公司 | 连续培养雨声红球藻累积虾青素的方法 |
CN108753620A (zh) * | 2018-05-30 | 2018-11-06 | 昆明理工大学 | 一种提高雨生红球藻生物量和虾青素含量的方法 |
Non-Patent Citations (2)
Title |
---|
梁文艳等: "脉冲变频电磁场对水华鱼腥藻生长的效应", 《环境工程学报》 * |
谢友坪等: "脉冲式添加氮源对耐温微藻Desmodesmus sp. F51细胞生长和细胞组成的影响", 《食品科学》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101624570B (zh) | 中药培养养殖肉灵芝方法及养殖肉灵芝保健品的制备方法 | |
CN101760478B (zh) | 一种葛根红曲的制造方法 | |
CN106255421B (zh) | 大蒜发酵组合物的制造方法及大蒜发酵组合物 | |
CN105218695B (zh) | 一种黑果枸杞多糖提取物及其制备方法 | |
CN112057546A (zh) | 一种蜂胶灵芝孢子粉组合物及其制备方法和应用 | |
CN107596339A (zh) | 一种灵芝孢子粉活性肽的制备方法 | |
CN102971415B (zh) | 血小板源性生长因子-bb产生增强剂、以及包含该增强剂的间充质系干细胞产生促进剂、干细胞稳定剂和真皮再生剂 | |
CN102940650B (zh) | 用于解酒的蜂胶乙醇提取物、制备方法及在生产肠溶片中的应用 | |
CN105011150A (zh) | 一种海茸保健口服液的制备工艺 | |
CN107212392A (zh) | 一种全营养发酵养生食品及其制备方法 | |
CN102430110B (zh) | 复方发酵虫草菌粉前列地尔组合药物 | |
CN106389477B (zh) | 一种土生戈登氏菌的全细胞植物油提取物的制备方法和应用 | |
CN109998101A (zh) | 一种适用心脏调养人群的宇航民用营养配方 | |
CN103054906B (zh) | 用于解酒的蜂胶乙醇提取物、制备方法及在生产口含片中的应用 | |
CN109645295A (zh) | 一种维持心血管系统健康的雨生红球藻虾青素固体饮料 | |
Dos Santos et al. | Effects of Cordyceps sinensis on macrophage function in high-fat diet fed rats and its anti-proliferative effects on IMR-32 human neuroblastoma cells. | |
CN107156817A (zh) | 枸杞丰乳酵素 | |
CN103710264B (zh) | 一种灵芝孢子的破壁辅助添加剂 | |
CN112843172A (zh) | 提高人体机能和排出有害毒素的中西药组合物及其制备方法 | |
CN110607245A (zh) | 一种灵芝虫草胶囊及其制备方法 | |
CN101953857A (zh) | 复方发酵虫草菌粉(蝙蝠蛾拟青霉Cs-4菌粉)组合药物 | |
CN103705547A (zh) | 一种灵芝孢子的破壁处理剂 | |
CN102727863B (zh) | 复方发酵虫草菌粉人参皂苷Rg1组合药物 | |
CN116421678B (zh) | 用于治疗骨质疏松症的组合物、其制备方法及药物制剂 | |
CN107970437A (zh) | 虫草克癌基因肽 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190712 |
|
RJ01 | Rejection of invention patent application after publication |